Company intelligence / Profile preview

ProPhase BioPharma

Uniondale, New York, United States

Ownership: Public · PRPH
Development stage: Other

Overview

ProPhase BioPharma is advancing clinical programs including large-scale trials for the antiviral Equivir and preclinical/early clinical investigation of Linebacker LB-1 and LB-2 as small molecule PIM kinase inhibitors for cancer, infection, and neurological diseases. BE-Smart diagnostic test for esophageal cancer is in late-stage validation, with commercial launch expected after regulatory coding is secured (anticipated H2 2024).

Therapeutic areas: OncologyInfectious DiseasesNeurology
Modalities: Small moleculeDietary supplementDiagnosticGenomics
Industry: Biotech

Drug pipeline

1 asset

Linebacker-1

Preclinical

Partnerships

Dana Farber Cancer Institute (development of LB-1 for cancer co-therapy)Genesis Clinical (diagnostic test stratification for BE-Smart)

Beyond the preview

Go deeper on ProPhase BioPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProPhase BioPharma.

Explore the full profile